Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...
The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results